24 results
8-A12B
EX-4.1
SAVA
Cassava Sciences Inc
3 Jan 24
Registration of securities on exchange
4:18pm
that such business purpose must remain confidential.
Section 5.03 Expenses. Subject to Section 2.04(c)(ii), all expenses incident to the Company’s
8-K
EX-4.1
SAVA
Cassava Sciences Inc
3 Jan 24
Entry into a Material Definitive Agreement
9:10am
expenses incident to the Company’s performance of or compliance with its obligations under this Article V relating to the issuance of the Warrant
8-A12G
EX-4.1
SAVA
Cassava Sciences Inc
2 Jan 24
Registration of securities
9:10am
that such business purpose must remain confidential.
Section 5.03 Expenses. Subject to Section 2.04(c)(ii), all expenses incident to the Company’s
8-K
EX-99.1
06xyjyetiicdh
11 Dec 23
Cassava Sciences Appoints
4:18pm
8-K
EX-1.1
qs0ubwcbjk2sl9acxt
1 May 23
Entry into a Material Definitive Agreement
5:26pm
8-K
EX-10.1
bdir8mz vulmh
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
8-K
EX-10.1
sstruc hybxmcklowzg1
11 Mar 21
Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam
4:59pm
8-K
EX-10.1
zz7cv5q
12 Feb 21
Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock
5:09pm
8-K
EX-1.1
rhkxdffc
13 Nov 20
Cassava Sciences Announces Proposed Public Offering of Common Stock
4:36pm
8-K
EX-10.1
ytmjm5rqqpfz
1 Sep 20
Departure of Directors or Certain Officers
5:00pm
8-K
EX-10.1
uzy6elpxek945e9n008
11 May 18
Departure of Directors or Certain Officers
5:29pm